Acute monocytic leukemia News and Research

RSS
Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Research may point to new paradigms in diagnosis, treatment of aggressive cancers

Research may point to new paradigms in diagnosis, treatment of aggressive cancers

Novel molecule inhibits cancer-causing transcription factors

Novel molecule inhibits cancer-causing transcription factors

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita commences IND-enabling studies for its first oncology drug candidate

UVA researchers develop compound that could lead to improved leukemia treatments

UVA researchers develop compound that could lead to improved leukemia treatments

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Study shows that reprogramming stem cells can prevent cancer following full body radiation

Study shows that reprogramming stem cells can prevent cancer following full body radiation

Novel marker may help doctors choose most effective treatment for older patients with AML

Novel marker may help doctors choose most effective treatment for older patients with AML

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Findings open new avenues for research to predict risk of therapy-related AML

Findings open new avenues for research to predict risk of therapy-related AML

Combination therapy benefits patients with acute myeloid leukemia

Combination therapy benefits patients with acute myeloid leukemia

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML

Two-drug combination may be effective for patients with higher-risk forms of MDS and AML